Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime

Area of Science:

• Cardiovascular Medicine
• Endothelial Biology
• Metabolomics

Background:

• Hypertension and dyslipidemia, known as silent killers, significantly increase atherosclerosis risk.
• Endothelial cell dysfunction is a shared pathophysiological mechanism underlying both hypertension and dyslipidemia.
• This dysfunction involves dysregulation of homeostasis, redox balance, vascular tone, inflammation, and thrombosis.

Purpose of the Study:

• To characterize the endothelium's role in hypertension and dyslipidemia development.
• To identify promising therapeutic strategies targeting endothelial dysfunction.
• To explore the impact of recent advancements in diagnostics and bioinformatics.

Main Methods:

• Review of current literature on endothelial function in hypertension and dyslipidemia.
• Analysis of metabolomic research identifying novel therapeutic targets.
• Evaluation of state-of-the-art diagnostic and risk stratification approaches.

Main Results:

• Endothelial dysfunction is a key factor linking hypertension and dyslipidemia, exacerbating atherosclerosis.
• Metabolomic studies have uncovered new therapeutic targets for these conditions.
• Integrated approaches using clinical data, imaging, omics, and AI enhance patient risk stratification and treatment.

Conclusions:

• Targeting mediators of endothelial dysfunction presents a promising therapeutic avenue.
• Novel endothelial biomarkers and bioinformatics offer new perspectives for patient management.
• Understanding endothelial pathomechanisms is crucial for combating hypertension and dyslipidemia.